Xeris Biopharma reports record Q4 revenue $85.8M (+43% YoY); net income $11.1M, provides FY2026 guidance $375-390M

Xeris Biopharma Holdings, Inc.

Q4 total revenue $85.8M (+42.8% YoY); net income $11.1M vs net loss $5.1M in Q4 2024.
Recorlev Q4 revenue $45.3M (+100% YoY); FY2025 total revenue $291.8M (+43.7% YoY).
FY2026 total revenue guidance $375M-$390M, >30% growth at midpoint.
Adjusted EBITDA Q4 $25.1M, improvement of $16.8M vs prior year.
Company expects timely execution of XP-8121 Phase 3 trial; remains focused on capital deployment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.